ロード中...
S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer
The development of resistance to EGFR Tyrosine kinase inhibitors (TKIs) in NSCLC with activating EGFR mutations is a critical limitation of this therapy. In addition to genetic alterations such as EGFR secondary mutation causing EGFR-TKI resistance, compensatory activation of signaling pathways with...
保存先:
| 出版年: | Oncogene |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7718330/ https://ncbi.nlm.nih.gov/pubmed/33037411 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41388-020-01497-4 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|